Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 8/20 | 0.32 |
| ▸ | ENO1 | P06733 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894171 | 0.90 | ELANE (0.34) | USP2CYP3A4ELANEADRB3HPGD | |
| SCHEMBL9279337 | 0.86 | PLA2G10 (0.40) | POLBELANEHPGD | |
| SCHEMBL9222247 | 0.86 | PLA2G10 (0.40) | POLBELANEHPGD | |
| SCHEMBL7809155 | 0.83 | NPSR1 (0.41) | CYP3A4CHRM1ELANEADRB2ADRB1 | |
| SCHEMBL8826028 | 0.83 | NPSR1 (0.41) | CYP3A4CHRM1ELANEADRB2ADRB1 | |
| SCHEMBL3896668 | 0.82 | NPSR1 (0.34) | ELANEADRB2ADRB1ADRB3HPGD | |
| SCHEMBL9223494 | 0.78 | TDP1 (0.39) | ELANE | |
| SCHEMBL9273334 | 0.78 | TDP1 (0.39) | ELANE | |
| SCHEMBL9663985 | 0.74 | NPSR1 (0.35) | — | |
| SCHEMBL7756429 | 0.73 | MEN1 (0.35) | POLBELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538212-B2 | Intermediate for carbapenem compound for oral administration and process for producing the same | KANEKA CORPORATION (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20060252929-A1 | Novel intermediate for carbapenem compound for oral administration and process for producing the same | KANEKA CORPORATION (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1582526-A1 | NOVEL INTERMEDIATE FOR CARBAPENEM COMPOUND FOR ORAL ADMINISTRATION AND PROCESS FOR PRODUCING THE SAME | KANEKA CORPORATION (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252929-A1 | Novel intermediate for carbapenem compound for oral administration and process for producing the same | B2M, MGAM, PKM | USP2 2578/4885CYP3A4 15/4885CHRM1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.